AXA reduced its stake in BioTime, Inc. (NYSEAMERICAN:BTX) by 8.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,101,975 shares of the biotechnology company’s stock after selling 199,682 shares during the period. AXA owned 1.66% of BioTime worth $4,940,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Destination Wealth Management bought a new position in BioTime during the third quarter worth about $1,237,000. Bank of New York Mellon Corp lifted its holdings in BioTime by 4.7% during the second quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock worth $1,534,000 after acquiring an additional 33,350 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in BioTime by 5.2% during the second quarter. Northern Trust Corp now owns 1,016,226 shares of the biotechnology company’s stock worth $2,094,000 after acquiring an additional 49,778 shares in the last quarter.

Separately, Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a research note on Wednesday, October 3rd.

BioTime stock opened at $1.34 on Friday. BioTime, Inc. has a 52 week low of $1.28 and a 52 week high of $3.16.

BioTime (NYSEAMERICAN:BTX) last posted its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.75 million.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company’s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Further Reading: What are the Benefits of Index Funds?

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioTime and related companies with’s FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *